Pentraxin 3 (PTX3) Is Associated with Severe Sepsis and Fatal Disease in Emergency Room Patients with Suspected Infection: A Prospective Cohort Study

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Uusitalo Seppälä, Raija ^a   Huttunen, Reetta ^b,c   Aittoniemi, Janne ^d   Koskinen, Pertti ^e,f   Leino, Aila ^e,f   Vahlberg, Tero ^e   Rintala, Esa M ^f  

^a SATAKUNTA CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^d FIMLAB LABORATORIES   (Finland)

^e Turku University   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTISONE; CREATININE; INTERLEUKIN 6; PENTRAXIN 3; PROCALCITONIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALCOHOL ABUSE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; EMERGENCY PATIENT; EMERGENCY WARD; ENZYME LINKED IMMUNOSORBENT ASSAY; FATALITY; FEMALE; HUMAN; HYPOTENSION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PREDICTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEPSIS; SOLID PHASE SYNTHESIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CALCITONIN; COHORT STUDIES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT ADMISSION; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; REGRESSION ANALYSIS; ROC CURVE; SEPSIS; SERUM AMYLOID P-COMPONENT; YOUNG ADULT;

BACTERIA (MICROORGANISMS);

EID: 84872343230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053661     Document Type: Article

References (42)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303-1310.
2. Kumar A, Haery C, Paladugu B, Kumar A, Symeoneides S, et al. (2006) The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 193: 251-258.
3. Zambon M, Ceola M, Almeida-de-Castro R, Gullo A, Vincent JL, (2008) Implementation of the Surviving Sepsis Campaign guidelines for severe sepsis and septic shock: we could go faster. J Crit Care 23: 455-460.
4. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95.
5. Marshall JC, Reinhart K, (2009) Biomarkers of sepsis. Crit Care Med 37: 2290-2298.
6. Clyne B, Olshaker JS, (1999) The C-reactive protein. J Emerg Med 17: 1019-1025.
7. Povoa P, Coelho L, Almeida E, Fernandes A, Mealha R, et al. (2005) C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect 11: 101-108.
8. Silvestre J, Povoa P, Coelho L, Almeida E, Moreira P, et al. (2009) Is C-reactive protein a good prognostic marker in septic patients? Intensive Care Med 35: 909-913.
9. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, et al. (2003) Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 31: 1737-1741.
10. Nakamura A, Wada H, Ikejiri M, Hatada T, Sakurai H, et al. (2009) Efficacy of procalcitonin in the early diagnosis of bacterial infections in a critical care unit. Shock 31: 586-591.
11. Tang H, Huang T, Jing J, Shen H, Cui W, (2009) Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 37: 497-507.
12. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, et al. (1992) Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 267: 22190-22197.
13. Lee GW, Lee TH, Vilcek J, (1993) TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 150: 1804-1812.
14. Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, et al. (1997) Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem 272: 8172-8178.
15. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, et al. (1997) Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 272: 32817-32823.
16. Introna M, Alles VV, Castellano M, Picardi G, De Gioia L, et al. (1996) Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 87: 1862-1872.
17. Mantovani A, Garlanda C, Doni A, Bottazzi B, (2008) Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 28: 1-13.
18. Garlanda C, Bottazzi B, Bastone A, Mantovani A, (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23: 337-366.
19. Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, et al. (2009) The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 227: 9-18.
20. de Kruif MD, Limper M, Sierhuis K, Wagenaar JF, Spek CA, et al. (2010) PTX3 predicts severe disease in febrile patients at the emergency department. J Infect 60: 122-127.
21. Muller B, Peri G, Doni A, Torri V, Landmann R, et al. (2001) Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 29: 1404-1407.
22. Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, et al. (2010) Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med 36: 621-629.
23. Huttunen R, Hurme M, Aittoniemi J, Huhtala H, Vuento R, et al. (2011) High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLoS One 6: e17653.
24. Sprong T, Peri G, Neeleman C, Mantovani A, Signorini S, et al. (2009) Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock 31: 28-32.
25. Uusitalo-Seppälä R, Huttunen R, Tarkka M, Aittoniemi J, Koskinen P, et al. (2012) Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med 272: 247-256.
26. Uusitalo-Seppälä R, Koskinen P, Leino A, Peuravuori H, Vahlberg T, et al. (2011) Early detection of severe sepsis in the emergency room: diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6. Scand J Infect Dis 43: 883-890.
27. Uusitalo-Seppälä R, Peuravuori H, Koskinen P, Vahlberg T, Rintala EM, (2012) Role of plasma bactericidal/permeability-increasing protein, group IIA phospholipase A(2), C-reactive protein, and white blood cell count in the early detection of severe sepsis in the emergency department. Scand J Infect Dis 44: 697-704.
28. Boyd JC (1997) Mathematical tools for demonstrating the clinical usefulness of biochemical markers. Scand J Clin Lab Invest Suppl 227: 46-63.
29. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864-874.
30. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, et al. (2009) Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 47: 471-477.
31. Vänskä M, Koivula I, Hämäläinen S, Pulkki K, Nousiainen T, et al. (2011) High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients. Haematologica 96: 1385-1389.
32. Garlanda C, Bottazzi B, Moalli F, Deban L, Molla F, et al. (2011) Pentraxins and atherosclerosis: the role of PTX3. Curr Pharm Des 17: 38-46.
33. Diamandis EP, Goodglick L, Planque C, Thornquist MD, (2011) Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res 17: 2395-2399.
34. Pulsatelli L, Peri G, Macchioni P, Boiardi L, Salvarani C, et al. (2010) Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica. Clin Exp Rheumatol 28: 756-758.
35. Mairuhu AT, Peri G, Setiati TE, Hack CE, Koraka P, et al. (2005) Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. J Med Virol 76: 547-552.
36. Wagenaar JF, Goris MG, Gasem MH, Isbandrio B, Moalli F, et al. (2009) Long pentraxin PTX3 is associated with mortality and disease severity in severe Leptospirosis. J Infect 58: 425-432.
37. Outinen TK, Mäkelä S, Huhtala H, Hurme M, Meri S, et al. (2011) High pentraxin-3 plasma levels associate with thrombocytopenia in acute Puumala hantavirus-induced nephropathia epidemica. Eur J Clin Microbiol Infect Dis 31: 957-963.
38. He X, Han B, Liu M, (2007) Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol 292: L1039-1049.
39. Napoleone E, di Santo A, Peri G, Mantovani A, de Gaetano G, et al. (2004) The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol 76: 203-209.
40. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A, (2008) Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 20: 538-544.
41. Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, et al. (2008) Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 36: 2302-2308.
42. Karlsson S, Varpula M, Ruokonen E, Pettilä V, Parviainen I, et al. (2007) Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 33: 435-443.